Emission characteristics of paliperidone from invega™ tablets in one-dose packages and the evaluation of patients

Hiroko Kito, Yasumi Ishida, Miki Kunimi, Yumiko Morooka, Takashi Hirowatari, Takahiro Akamine, Hana Hashimoto, Koyanagi Satoru, Shigehiro Ohdo, Hidetoshi Kamimura

Research output: Contribution to journalArticle

Abstract

Objectives Paliperidone tablets (INVEGA™) are dispensed in a sustained release preparation through osmotic pressure so that this drug is not prematurely pressed through the package before dosing and to avoid dispensing by the one-dose package. However, pressing through the package of the paliperidone tablet is hard and may be challenging for feeble patients. Therefore we dispensed the paliperidone tablet in a one-dose package and investigated the emission characteristics and impression of the patients. Methods We observed the appearance of the tablet and performed a dissolution test of the paliperidone tablet in the one-dose package. We also carried out a questionnaire survey for the patients administered the paliperidone tablets in the one-dose package. Results An appearance change of an INVEGA™ and amount fall of paliperidone were not noted for at least 90 days after preparation in the one-dose package. The emission characteristics of paliperidone from an INVEGA™ showed adapted behavior according to pharmaceutical standards for at least 90 days after preparation in the one-dose package. Seven of 8 patients replied that the one-dose package was useful to avoid missing doses. In addition, all patients hoped to receive medication by the one-dose package. Conclusions An improvement in medication adherence is anticipated for paliperidone using the one-dose package. (Jpn Pharmacol Ther 2016 ; 44 : 65-9).

Original languageEnglish
Pages (from-to)65-69
Number of pages5
JournalJapanese Pharmacology and Therapeutics
Volume44
Issue number1
Publication statusPublished - Jan 1 2016

Fingerprint

Tablets
Delayed-Action Preparations
Medication Adherence
Paliperidone Palmitate
Osmotic Pressure
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Kito, H., Ishida, Y., Kunimi, M., Morooka, Y., Hirowatari, T., Akamine, T., ... Kamimura, H. (2016). Emission characteristics of paliperidone from invega™ tablets in one-dose packages and the evaluation of patients. Japanese Pharmacology and Therapeutics, 44(1), 65-69.

Emission characteristics of paliperidone from invega™ tablets in one-dose packages and the evaluation of patients. / Kito, Hiroko; Ishida, Yasumi; Kunimi, Miki; Morooka, Yumiko; Hirowatari, Takashi; Akamine, Takahiro; Hashimoto, Hana; Satoru, Koyanagi; Ohdo, Shigehiro; Kamimura, Hidetoshi.

In: Japanese Pharmacology and Therapeutics, Vol. 44, No. 1, 01.01.2016, p. 65-69.

Research output: Contribution to journalArticle

Kito, H, Ishida, Y, Kunimi, M, Morooka, Y, Hirowatari, T, Akamine, T, Hashimoto, H, Satoru, K, Ohdo, S & Kamimura, H 2016, 'Emission characteristics of paliperidone from invega™ tablets in one-dose packages and the evaluation of patients', Japanese Pharmacology and Therapeutics, vol. 44, no. 1, pp. 65-69.
Kito, Hiroko ; Ishida, Yasumi ; Kunimi, Miki ; Morooka, Yumiko ; Hirowatari, Takashi ; Akamine, Takahiro ; Hashimoto, Hana ; Satoru, Koyanagi ; Ohdo, Shigehiro ; Kamimura, Hidetoshi. / Emission characteristics of paliperidone from invega™ tablets in one-dose packages and the evaluation of patients. In: Japanese Pharmacology and Therapeutics. 2016 ; Vol. 44, No. 1. pp. 65-69.
@article{19fe3721a05a47448c61b34c14dd8fff,
title = "Emission characteristics of paliperidone from invega™ tablets in one-dose packages and the evaluation of patients",
abstract = "Objectives Paliperidone tablets (INVEGA™) are dispensed in a sustained release preparation through osmotic pressure so that this drug is not prematurely pressed through the package before dosing and to avoid dispensing by the one-dose package. However, pressing through the package of the paliperidone tablet is hard and may be challenging for feeble patients. Therefore we dispensed the paliperidone tablet in a one-dose package and investigated the emission characteristics and impression of the patients. Methods We observed the appearance of the tablet and performed a dissolution test of the paliperidone tablet in the one-dose package. We also carried out a questionnaire survey for the patients administered the paliperidone tablets in the one-dose package. Results An appearance change of an INVEGA™ and amount fall of paliperidone were not noted for at least 90 days after preparation in the one-dose package. The emission characteristics of paliperidone from an INVEGA™ showed adapted behavior according to pharmaceutical standards for at least 90 days after preparation in the one-dose package. Seven of 8 patients replied that the one-dose package was useful to avoid missing doses. In addition, all patients hoped to receive medication by the one-dose package. Conclusions An improvement in medication adherence is anticipated for paliperidone using the one-dose package. (Jpn Pharmacol Ther 2016 ; 44 : 65-9).",
author = "Hiroko Kito and Yasumi Ishida and Miki Kunimi and Yumiko Morooka and Takashi Hirowatari and Takahiro Akamine and Hana Hashimoto and Koyanagi Satoru and Shigehiro Ohdo and Hidetoshi Kamimura",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "44",
pages = "65--69",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "1",

}

TY - JOUR

T1 - Emission characteristics of paliperidone from invega™ tablets in one-dose packages and the evaluation of patients

AU - Kito, Hiroko

AU - Ishida, Yasumi

AU - Kunimi, Miki

AU - Morooka, Yumiko

AU - Hirowatari, Takashi

AU - Akamine, Takahiro

AU - Hashimoto, Hana

AU - Satoru, Koyanagi

AU - Ohdo, Shigehiro

AU - Kamimura, Hidetoshi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives Paliperidone tablets (INVEGA™) are dispensed in a sustained release preparation through osmotic pressure so that this drug is not prematurely pressed through the package before dosing and to avoid dispensing by the one-dose package. However, pressing through the package of the paliperidone tablet is hard and may be challenging for feeble patients. Therefore we dispensed the paliperidone tablet in a one-dose package and investigated the emission characteristics and impression of the patients. Methods We observed the appearance of the tablet and performed a dissolution test of the paliperidone tablet in the one-dose package. We also carried out a questionnaire survey for the patients administered the paliperidone tablets in the one-dose package. Results An appearance change of an INVEGA™ and amount fall of paliperidone were not noted for at least 90 days after preparation in the one-dose package. The emission characteristics of paliperidone from an INVEGA™ showed adapted behavior according to pharmaceutical standards for at least 90 days after preparation in the one-dose package. Seven of 8 patients replied that the one-dose package was useful to avoid missing doses. In addition, all patients hoped to receive medication by the one-dose package. Conclusions An improvement in medication adherence is anticipated for paliperidone using the one-dose package. (Jpn Pharmacol Ther 2016 ; 44 : 65-9).

AB - Objectives Paliperidone tablets (INVEGA™) are dispensed in a sustained release preparation through osmotic pressure so that this drug is not prematurely pressed through the package before dosing and to avoid dispensing by the one-dose package. However, pressing through the package of the paliperidone tablet is hard and may be challenging for feeble patients. Therefore we dispensed the paliperidone tablet in a one-dose package and investigated the emission characteristics and impression of the patients. Methods We observed the appearance of the tablet and performed a dissolution test of the paliperidone tablet in the one-dose package. We also carried out a questionnaire survey for the patients administered the paliperidone tablets in the one-dose package. Results An appearance change of an INVEGA™ and amount fall of paliperidone were not noted for at least 90 days after preparation in the one-dose package. The emission characteristics of paliperidone from an INVEGA™ showed adapted behavior according to pharmaceutical standards for at least 90 days after preparation in the one-dose package. Seven of 8 patients replied that the one-dose package was useful to avoid missing doses. In addition, all patients hoped to receive medication by the one-dose package. Conclusions An improvement in medication adherence is anticipated for paliperidone using the one-dose package. (Jpn Pharmacol Ther 2016 ; 44 : 65-9).

UR - http://www.scopus.com/inward/record.url?scp=84960517560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960517560&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84960517560

VL - 44

SP - 65

EP - 69

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - 1

ER -